New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
09:18 EDTHDY, IRDM, GOGO, TWTR, BPI, ALNY, HSH, P, CLB, NIHD, SRO, PFOn The Fly: Pre-market Movers
HIGHER: Pinnacle Foods (PF), up 18% after agreeing to be acquired by Hillshire Brands (HSH) for $6.6B. Hillshire Brands is down 1.5% after the news... TESARO (TSRO), up 20% after rolapitant Phase 3 trial meets primary, secondary endpoints... Alnylam (ALNY), up 7.7% after naming new program ALN-HBV to its pipeline. UP AFTER EARNINGS: Gogo (GOGO), up 8.6%. UP AFTER UPGRADES: Pandora (P), up 3.2% after upgraded at MKM Partners... Twitter (TWTR), up 3.1% following upgrade at SunTrust... Peabody (BTU), up 3.8% after upgraded at Morgan Stanley... Iridium (IRDM), up 4% following upgrade at Macquarie. DOWN AFTER EARNINGS: NII Holdings (NIHD), down 10%... Bridgepoint Education (BPI), down 12%... Hyperdynamics (HDY), down 11%. ALSO LOWER: Core Laboratories (CLB), down 12% after lowering earnings outlook.
News For P;TWTR;PF;HSH;GOGO;SRO;ALNY;IRDM;NIHD;BPI;HDY;CLB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 17, 2014
17:03 EDTALNYAlnylam presents new pre-clinical data on RNAi therapeutic programs
Subscribe for More Information
16:00 EDTTWTROptions Update; November 17, 2014
Subscribe for More Information
10:02 EDTPFOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: CyrusOne (CONE) upgraded to Buy from Hold at Stifel... MGIC Investment (MTG) upgraded to Conviction Buy from Buy at Goldman... NuVasive (NUVA) upgraded to Outperform from Market Perform at Wells Fargo... Phillips 66 (PSX) upgraded to Outperform from Neutral at Credit Suisse... Pinnacle Foods (PF) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Outperform from Sector Perform at RBC Capital.. Thoratec (THOR) upgraded to Outperform from Market Perform at Wells Fargo... Volcano (VOLC) upgraded to Outperform from Neutral at Credit Suisse... Progressive Waste (BIN) upgraded to Neutral from Underperform at Macquarie... Clean Harbors (CLH) upgraded to Outperform from Neutral at Wedbush... McGraw Hill Financial (MHFI) upgraded to Buy from Hold at Benchmark Co... Chesapeake (CHK) upgraded to Outperform from Market Perform at Bernstein... American Science & Engineering (ASEI) upgraded to Fair Value from Sell at CRT Capital... Sony (SNE) upgraded to Overweight from Equal Weight at Morgan Stanley.
09:42 EDTPPandora management to meet with JPMorgan
Meeting to be held in Boston on November 19 hosted by JPMorgan.
09:36 EDTTWTRActive equity options trading
Active equity options trading according to Track Data: AAPL PBR BHI GILD MU HD AMZN TSLA YHOO FB TWTR
07:09 EDTALNYAmerican Heart Association to hold a conference
Subscribe for More Information
06:38 EDTPFPinnacle Foods upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Pinnacle Foods to Buy citing market share gains and an improved balance sheet . The firm raised its price target for shares to $37 from $34.
November 16, 2014
18:57 EDTPSirius loses request to dismiss Turtles' lawsuit on pre-1972 songs, NYT says
Subscribe for More Information
November 14, 2014
16:26 EDTTWTRNasdaq clear leader as major averages end week higher
Subscribe for More Information
16:21 EDTPOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTTWTROptions Update; November 14, 2014
Subscribe for More Information
12:58 EDTPOn The Fly: Midday Wrap
Subscribe for More Information
11:22 EDTPPandora rallies after CEO share purchase
The stock is being pushed higher by word that the CEO of the company made a purchase of 25,000 shares following the recent lows at $17.55. At the current price of $20.97 resistance is at the bottom of the bearish gap down in price from October 24th at $21.17. A move higher puts the shares back into the gap for a bullish gap fill. Resistance would be at $22.48 thereafter. Support is at $20.31. Approximately 10% of the float is short which is likely contributing to a squeeze higher.
11:05 EDTPPandora jumps following CEO share purchase
Shares of Pandora (P) are rallying after the company's CEO disclosed that he had bought 25,000 shares of the company's stock. WHAT'S NEW: In a regulatory filing last night, Pandora CEO Brian McAndrews disclosed that he had bought 25,000 of the company's shares on Wenesday at a price of $18.58 per share. McAndrews now owns over 475,000 shares of the stock, according to the filing. ANALYST REACTION: In a note to investors, Stifel analyst Scott Devitt wrote that McAndrews purchased the stock using his own personal funds. According to the analyst, it is quite rare for CEOs to take such an action. McAndrews' purchase of the stock was "a strong vote of confidence" in the company, Devitt contended. He kept a $29 price target and Buy rating on the shares. WHAT'S NOTABLE: Pandora announced that it would hold a conference call next Tuesday to discuss proceedings before the Copyright Royalty Board. The board will determine the company's new royalty structure by December 2015, Devitt wrote. PRICE ACTION: In mid-morning trading, Pandora climbed $2.30, or 12.5%, to $20.75.
10:10 EDTGOGOOptions with decreasing implied volatility
Subscribe for More Information
09:38 EDTTWTR, PActive equity options trading
Subscribe for More Information
08:32 EDTPFPinnacle Foods to acquire Garden Proten International for C$175M
Subscribe for More Information
08:18 EDTPPandora CEO share purchases a significant vote of confidence, says Stifel
Subscribe for More Information
06:31 EDTALNYAlnylam to host conference call
Subscribe for More Information
06:04 EDTALNYAlnylam announces positive initial phase 2 data with Revusiran
Alnylam announced positive initial Phase 2 data with revusiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of TTR cardiac amyloidosis. In the pilot Phase 2 study, revusiran was found to be generally well tolerated in TTR cardiac amyloidosis patients. Revusiran demonstrated clinical activity with an up to 98.2% knockdown of serum TTR – the disease causing protein. This included similar knockdown effects toward wild type and mutant TTR protein within V122I patients, who represent the most common genotype associated with inherited forms of TTR cardiac amyloidosis. In the five week course of treatment, there were no significant changes observed in a number of exploratory clinical measurements. Revusiran utilizes Alnylam’s proprietary GalNAc-conjugate delivery platform that enables subcutaneous delivery of RNAi therapeutics with a wide therapeutic index. The primary objective of the study was to evaluate the safety and tolerability of revusiran. The secondary objectives were to assess the clinical activity of revusiran toward serum levels of TTR and characterize the drug’s pharmacokinetic profile. In addition, a number of exploratory clinical measurements were performed at baseline and days 42 and 90 after start of dosing.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use